Becker's Healthcare April 9, 2024
Mariah Taylor

Biosimilars can now be substituted as part of regular formulary maintenance changes, according to CMS’ Medicare Advantage and Part D Final Rule for 2025. However, the change could significantly increase patient cost sharing, according to an article on the American Society of Health-System Pharmacists website.

The biosimilar substitution rule would apply to all enrollees, including those taking the reference product prior to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare Advantage, Patient / Consumer, Pharma / Biotech
Hospice remains a blind spot for Medicare Advantage
For Dually Eligible Individuals, Medicare Brokers Are 'Broken'
Risk Adjustment and Incentives for Upcoding in Medicare
Podcast: The Rise – and Future – of Medicare Advantage w/ Jack Hoadley
Medicare Advantage extras on the chopping block in 2025

Share This Article